Additional Relevant Details In December 2016, AbbVie's main US filed patent on HUMIRA will expire and allow for the generic manufacturing of the drug.  HUMIRA is AbbVie's most profitable product, accounting for 61% of total revenues in 2015.  However, AbbVie still has over 50 patents still protecting HUMIRA and sales shouldn't be affected until those expire in at least several years